150 related articles for article (PubMed ID: 18628460)
1. Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer.
Shields AF; Lawhorn-Crews JM; Briston DA; Zalzala S; Gadgeel S; Douglas KA; Mangner TJ; Heilbrun LK; Muzik O
Clin Cancer Res; 2008 Jul; 14(14):4463-8. PubMed ID: 18628460
[TBL] [Abstract][Full Text] [Related]
2. Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.
Trigonis I; Koh PK; Taylor B; Tamal M; Ryder D; Earl M; Anton-Rodriguez J; Haslett K; Young H; Faivre-Finn C; Blackhall F; Jackson A; Asselin MC
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):682-93. PubMed ID: 24504503
[TBL] [Abstract][Full Text] [Related]
3. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
4. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
[TBL] [Abstract][Full Text] [Related]
5. Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.
de Langen AJ; Klabbers B; Lubberink M; Boellaard R; Spreeuwenberg MD; Slotman BJ; de Bree R; Smit EF; Hoekstra OS; Lammertsma AA
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):389-95. PubMed ID: 18931838
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
[TBL] [Abstract][Full Text] [Related]
7. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
8. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
9. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Kimura N; Ishikawa S; Okuda M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):236-45. PubMed ID: 17909790
[TBL] [Abstract][Full Text] [Related]
10. Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.
Frings V; Yaqub M; Hoyng LL; Golla SS; Windhorst AD; Schuit RC; Lammertsma AA; Hoekstra OS; Smit EF; Boellaard R;
J Nucl Med; 2014 Sep; 55(9):1417-23. PubMed ID: 24970910
[TBL] [Abstract][Full Text] [Related]
11. Parametric Method Performance for Dynamic 3'-Deoxy-3'-
Kramer GM; Frings V; Heijtel D; Smit EF; Hoekstra OS; Boellaard R;
J Nucl Med; 2017 Jun; 58(6):920-925. PubMed ID: 28572289
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.
Frings V; van der Veldt AA; Boellaard R; Herder GJ; Giovannetti E; Honeywell R; Peters GJ; Thunnissen E; Hoekstra OS; Smit EF
PLoS One; 2013; 8(5):e63705. PubMed ID: 23717468
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
16. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
[TBL] [Abstract][Full Text] [Related]
17. Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.
Frings V; de Langen AJ; Yaqub M; Schuit RC; van der Veldt AA; Hoekstra OS; Smit EF; Boellaard R
Mol Imaging Biol; 2014 Feb; 16(1):136-45. PubMed ID: 23813332
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
19. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM
J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832
[TBL] [Abstract][Full Text] [Related]
20. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]